The Real Reasons People Microdose GLP-1s People are microdosing GLP-1s because the standard treatment is either too expensive, unavailable due to shortages, or physically punishing
Interpretation and Limitations The researchers noted several limitations, including enrollment restricted to patients with obesity, a predominantly White study population, and the absence of alcohol-use follow-up following week 26
In type 2 diabetes trials (the SUSTAIN program), Ozempic produced an average weight loss of around 4.5 kg to 6.5 kg (roughly 10 to 14 lbs) over 52 weeks, depending on the dose
Although this setup is ideal, its physical implementation during the COVID-19 era is challenging, and based on the size and curation of both our testing arms of this study we assume such test results would not differ materially from the present study
doi:10.3390/jcm14113812 10.Jastreboff AM, Ryan DH, Bays HE, et al